The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
A phase II/III randomized trial of two doses of MK-3475 versus docetaxel in previously treated subjects with non-small cell lung cancer.
Roy S. Herbst
No relevant relationships to disclose
Alfonso Gurpide
Research Funding - Merck
Veerle Surmont
No relevant relationships to disclose
Dong-Wan Kim
No relevant relationships to disclose
Saiama Naheed Waqar
No relevant relationships to disclose
Judith Herder
No relevant relationships to disclose
Dae Ho Lee
No relevant relationships to disclose
Enric Carcereny
No relevant relationships to disclose
Noemi Reguart
No relevant relationships to disclose
John M. Wallmark
No relevant relationships to disclose
Suresh S. Ramalingam
No relevant relationships to disclose
Corey J. Langer
Consultant or Advisory Role - Merck (U)
Research Funding - Merck
Gregory M. Lubiniecki
Employment or Leadership Position - Merck
James Knowles
Employment or Leadership Position - Merck
Honghong Zhou
Employment or Leadership Position - Merck
Stock Ownership - Merck
Mary Elizabeth Hanson
Employment or Leadership Position - Merck
Stock Ownership - Merck
Paul Baas
No relevant relationships to disclose